Fig. 1
From: Proteomic profiling of plasma biomarkers in acute ischemic stroke due to large vessel occlusion
Flow diagram of the study design. Discovery phase: proteomic analysis of AIS patients due to LVO (4 groups, 10 individuals pooled in a group) versus healthy controls (2 groups, 10 individuals pooled in a group). Validation phase: Western blot analysis of selected plasma biomarkers in healthy controls (n = 33), patients with AIS due to non-LVO (n = 33), and patients with AIS due to LVO (n = 33). Patients with AIS due to LVO were further divided into two subgroups, AIS with good collaterals (n = 17) and poor collaterals (n = 16)